Skip to main content
TipRanks
Go Ultimate75% OFF
Hansa Biopharma AB logo

Hansa Biopharma AB: Valuation, Funding & Investors

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Hansa's portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy that facilitates kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with potential for redosing. Based in Lund, Sweden, Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$131M
Total Funding Rounds
2
Latest Funding Amount
$60M
Latest Funding Round
Investment

Main Enterprise Clients

A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Oct 08, 2025Investment$60.00M―
Oct 08, 2025Investment$71.30M―

Investors

Investor NameFunding Round
Polar Capital LLPInvestment
Redmile GroupInvestment

Similar Companies

A snapshot of private companies similar to Hansa Biopharma AB, helping you discover and navigate related company profiles.

Related News and Analysis